Skip to main content
. Author manuscript; available in PMC: 2012 Aug 1.
Published in final edited form as: Cancer Discov. 2011 Jun 17;1(3):248–259. doi: 10.1158/2159-8290.CD-11-0085

Figure 5. mTOR kinase inhibition-induced reactivation of AKT substrates is HER2 and PI3K dependent.

Figure 5

(A) BT-474 cells were treated with 500nM of AZD8055 and collected at the indicated times and lysates immunoblotted with indicated antibodies (panel 1 is the same as Figure 2A panel 1). After eight hours of AZD8055 treatment, the cells were treated with either 1μM of PI-103 (panel 2), or 200nM of lapatinib (panel 3 in A). Each inhibitor was added for one additional hour (indicated as time 9), four extra hours (indicated as time 12) or sixteen extra hours (indicated as time 24) and the lysates were immunoblotted with the indicated antibodies (see also Figure S4). (B) BT-474 cells were treated simultaneously with both 500nM AZD8055 and 1μM of lapatinib and were collected at the indicated times and lysates immunoblotted with indicated antibodies.